Cala Health, a Burlingame, Calif.-based bioelectronic medicine company setting a new standard of patient care for chronic disease, raised $77m in funding.
The round was led by Ascension Ventures with participation from new investors Dolby Family Ventures; PEAK6 Strategic Capital, a division of PEAK6 Investments; and Innovatus Capital Partners and all existing investors.
The company intends to use the funds to expand patient access and accelerate innovation, opening opportunities to explore indications beyond essential tremor, including other neurological indications like Parkinson’s disease as well as targets in psychiatry, cardiology and autoimmune disorders.
Led by Renee Ryan, CEO, Cala Health is a bioelectronic medicine company advancing wearable neuromodulation therapies that merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. Its lead product, Cala Trio™, is a non-invasive prescription therapy for essential tremor. New therapies are under development in Parkinson’s disease and other indications in neurology, as well as targets in psychiatry, cardiology and autoimmune disorders.
FinSMEs
16/11/2021